atopic dermatitis

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
BioSpace
Triveni Bio
funding
atopic dermatitis
Flag link:
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
AbbVie’s Rinvoq shows long-term sustained efficacy in atopic dermatitis
Clinical Trials Arena
AbbVie
clinical trials
Rinvoq
atopic dermatitis
Flag link:
Aclaris finishes enrolment in atopic dermatitis Phase IIb trial of ATI-1777
Aclaris finishes enrolment in atopic dermatitis Phase IIb trial of ATI-1777
Clinical Trials Arena
Aclaris
ATI-1777
atopic dermatitis
JAK inhibitors
Flag link:
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues
BioSpace
Eli Lilly
lebrikizumab
atopic dermatitis
eczema
FDA
drug manufacturing
Flag link:
Nektar Flags Lilly’s Miscalculations in Rezpeg Atopic Dermatitis Trials
Nektar Flags Lilly’s Miscalculations in Rezpeg Atopic Dermatitis Trials
BioSpace
Nektar Therapeutics
Eli Lill
Rezpeg
atopic dermatitis
Flag link:
Incyte’s trial of ruxolitinib cream meets primary endpoint
Incyte’s trial of ruxolitinib cream meets primary endpoint
Clinical Trials Arena
Incyte
ruxolitinib
clinical trials
pediatric
atopic dermatitis
Flag link:
Apogee Files for IPO with Promising Preclinical Immuno Asset
Apogee Files for IPO with Promising Preclinical Immuno Asset
BioSpace
Paragon Therapeutics
IPOs
asthma
atopic dermatitis
Flag link:
Eli Lilly unveils new data from atopic dermatitis therapy trials
Eli Lilly unveils new data from atopic dermatitis therapy trials
Clinical Trials Arena
Eli Lilly
clinical trial
eczema
atopic dermatitis
lebrikizumab
Flag link:
BenevolentAI lead atopic dermatitis drug misses the mark
BenevolentAI lead atopic dermatitis drug misses the mark
Pharmaphorum
BenevolentAI
clinical trials
BEN-2293
atopic dermatitis
Flag link:
First Protein Degrader Tested Outside Oncology Yields Promising Results
First Protein Degrader Tested Outside Oncology Yields Promising Results
BioSpace
Kymera Therapeutics
Sanofi
protein degradation
hidradenitis suppurativa
atopic dermatitis
KT-474
Flag link:
Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet
Weeks after starting, Amgen flashes yellow light on PhIII of $400M eczema bet
Endpoints
Amgen
Kyowa Kirin
clinical trials
AMG 451
atopic dermatitis
Flag link:
Key data catalysts for the industry’s small players
Key data catalysts for the industry’s small players
EP Vantage
Intercept Pharma
Akero
NASH
Kymera
atopic dermatitis
Zealand Pharma
short bowel syndrome
Relmada
Verona
Anavex
Assembly Biosciences
Aldeyra
Flag link:
FDA approves Sanofi and Regeneron’s Dupixent for atopic dermatitis in young children
FDA approves Sanofi and Regeneron’s Dupixent for atopic dermatitis in young children
Pharmaceutical Business Review
Sanofi
Regeneron
FDA
pediatric
atopic dermatitis
Dupixent
Flag link:
Sidekick and Pfizer prep launch of DTx for atopic dermatitis
Sidekick and Pfizer prep launch of DTx for atopic dermatitis
Pharmaforum
Pfizer
Sidekick Health
digital therapeutics
DTx
atopic dermatitis
Flag link:
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Fierce Biotech
Eli Lilly
lebrikizumab
Demira
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Fierce Biotech
Novartis
Incyte
JAK inhibitors
Opzelua
eczema
atopic dermatitis
Flag link:
Is Pfizer About to Have Another Megablockbuster Drug in Its Lineup?
Is Pfizer About to Have Another Megablockbuster Drug in Its Lineup?
Motley Fool
Pfizer
abrocitinib
atopic dermatitis
Flag link:
Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema
Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema
Fierce Pharma
Pfizer
Sanofi
Regeneron
FDA
Cibinqo
atopic dermatitis
Flag link:
Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals
Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals
NASDAQ
Eli Lilly
lebrikizumab
monoclonal antibodies
atopic dermatitis
clinical trials
Flag link:
A Pfizer Drug Moves Closer to Approval in Another Important Indication
A Pfizer Drug Moves Closer to Approval in Another Important Indication
Motley Fool
Cibingo
Pfizer
Europe
eczema
atopic dermatitis
Flag link:

Pages